Intraday Overview | The three major indices fell sharply, and the science index fell more than 3%; auto stocks and pharmaceutical outsourcing concept stocks weakened; after ideal car performance, it plummeted nearly 20%
The Hang Seng Index fell 2.2%, and the Tech Net Index fell by 3.41%; most of the shares fell by more than 7%, JD Health and NIO by more than 6%, Bilibili by more than 5%, and Tencent, Ali, Baidu, and NetEase by more than 3%.
The biotechnology sector of Hong Kong stocks weakened, with Zaiding Pharmaceuticals falling more than 6%, Pharmaceutical Kangde falling more than 5%, and Pharmaceutical Biotech and Zhaoyan New Pharmaceutical falling.
The biotechnology sector of Hong Kong stocks weakened, with Zaiding Pharmaceuticals falling more than 6%, Pharmaceutical Kangde falling more than 5%, and Pharmaceutical Biotech and Zhaoyan New Pharmaceutical falling.
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Intraday Overview | Tech Index rose more than 1%, and TechNet stocks were trending strongly. Bilibili rose more than 6%; Tencent Music rose more than 9% after its performance
Technology Network stocks rose collectively, with Bilibili up more than 6%, Kuaishou and Xiaomi Group up more than 3%; auto stocks improved, Great Wall Motor rose more than 7%, NIO rose nearly 6%, and Zero Sports Auto rose nearly 5%.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Intraday quick overview | The Science Index rose more than 1% to reach the 4,000 mark; port transport stocks were strong, and COSCO Marine Control rose more than 6%
Water stocks soared across the board. China Water Services rose more than 9%, Beijing Water Group rose more than 8%; high-speed rail infrastructure stocks collectively rallied, CRRC rose more than 9%, and Times Electric rose nearly 7%.
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Zhaoyan New Pharmaceutical (06127) cooperated with a professional investment institution to participate in the establishment of an industrial fund to complete the commercial registration procedure
Zhitong Finance App News, Zhaoyan New Pharmaceutical (06127) issued an announcement. On February 5, 2024, the company held the 6th meeting of the 4th board of directors and the first special meeting of independent directors in 2024 to review and pass the “Proposal on Cooperation between the Company and Professional Investment Institutions to Participate in the Investment Establishment of Industrial Funds and Related Transactions”, agreeing that the company and Wuxi Guolian Industrial Investment Private Equity Fund Management Co., Ltd., Beijing Hongru Heyu Investment Management Co., Ltd., and Jiangsu Yuanli Industrial Investment Co., Ltd. signed the “Wuxi Jinyifu New Biomedical Venture Capital” Partnership (limited partnership)
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | May 9
According to data disclosed on May 8, 2024, Yingfu Fund (02800.HK), Hang Seng China Enterprise (02828.HK), and Beijing Finance International (01468.HK) Hong Kong Stock Connect held the largest share value added, increasing by 3.94%, 3.05%, and 2.26% respectively; Zhaoyan New Pharmaceutical (06127.HK), Southern Hang Seng Technology (03033.HK), and Jinli Yongmagnetic (06680.HK) Hong Kong Stock Connect shares decreased the most, decreasing by -1.21%, -0.55%, and -0.5%, respectively 0.49%
Zhaoyan Pharmaceutical (06127) repurchased 276,800 A-share shares on May 7 at a cost of 4.9982 million yuan
Zhitong Finance App News, Zhaoyan New Pharmaceutical (06127) announced that on May 7, 2024, the company repurchased the company's A shares for the first time through centralized bidding. The number of shares repurchased was 276,800 shares, accounting for 0.0369% of the company's total shares as of the date of this announcement. The highest repurchase price was RMB 18.15 yuan/share, the minimum repurchase price was RMB 17.93 yuan/share, and the total capital used was RMB 4.9982 million (excluding transaction fees).
Hong Kong Stock Afternoon Review | The three major indices of Hong Kong stocks pulled back, and the Tech Index fell nearly 2%; PV stocks reversed the market, and GCL Technology rose more than 6%
Technology Network stocks declined; Bilibili fell more than 6%, NetEase fell more than 4%, Kuaishou and Meituan fell nearly 4%; as concept stocks declined, Huazhu Group fell more than 3%, and Jiumaojiu fell nearly 3%.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Zhitong Hong Kong Stock Exchange Unravels | A-shares make up gains and continues to boost Hong Kong stocks need to be wary of attacking Rafah
The current problem with Hong Kong stocks is nothing more than a matter of profit digestion, but under the stimulus of the money-making effect, the entry of incremental capital is expected to form a hedge
Hong Kong Stock Afternoon Review | The three major indices fluctuated slightly, pharmaceutical stocks strengthened against the market, and Pharmaceutical Biotech rose more than 5%
Most Technet stocks weakened, with Kuaishou falling nearly 2%, Meituan, Xiaomi, and Bilibili falling more than 1%; travel and tourism stocks generally rising, with Ctrip Group rising nearly 3%, Hong Kong China Travel up more than 2%, and Tongcheng Travel up more than 1%.
Intraday Overview | The three major indices of Hong Kong stocks weakened slightly, and the pharmaceutical outsourcing concept rose against the market
Road transport stocks strengthened; Guangzhou-Shenzhen Railway shares rose more than 9%, Anhui Wantong Expressway rose more than 6%; domestic housing stocks collectively pulled back, Agile Group fell more than 6%, and Midea Real Estate fell more than 5%.
The CXO sector of Hong Kong stocks strengthened collectively: Zhaoyan Pharmaceutical rose nearly 7%, and Kingsley rose more than 5%
Glonghui, May 6 | Hong Kong pharmaceutical stocks rose as a whole. Among them, innovative drugs and CXO showed the most prominent performance. In terms of individual CXO stocks, Zhaoyan Pharmaceutical, Kanglong Chemical, Pharmaceutical and Tiger Pharmaceuticals rose more than 6%, Kingsley rose more than 5%, Gloria Ying rose nearly 5%, and Pharmaceutical Kangde rose more than 3%.
Express News | The turbulence in the innovative drug sector boosted the rise and fall of Zhaoyan's new drugs
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | May 6
The Zhitong Finance App learned that according to data disclosed on May 3, 2024, Zhaoyan Pharmaceutical (06127), Vanke Enterprise (02202), and Guangshen Railway Co., Ltd. (00525) had the largest share added value, increasing by 1.23%, 1.21%, and 1.20% respectively; Dongfang Electric (01072), COSCO Marine Holdings (01919), and Poly Industries (06049) had the biggest reduction in Hong Kong Stock Connect shares, which decreased by -1.73%, -0.85%, and -0.70% respectively. In the last 5 trading days with statistics, Longyuan Electric Power (00916) and Guang
JOINN LABORATORIES(6127.HK):WAITING LONGER FOR RECOVERY TO MATERIALIZE
Joinn reported 1Q24 revenue of RMB325mn, down 12.1% YoY, and booked attributable
Nomura Adjusts Joinn Laboratories' Price Target to HK$10.41 From HK$12.60, Keeps at Neutral
05:40 AM EDT, 04/30/2024 (MT Newswires) -- Nomura Adjusts Joinn Laboratories' Price Target to HK$10.41 From HK$12.60, Keeps at Neutral Price (HKD): $8.31, Change: $-1.58, Percent Change: -15.98%
No Data